AbbVie Inc. will have direct competition for its presbyopia product Vuity, since privately held Orasis Pharmaceuticals Ltd. got US Food and Drug Administration approval for the same indication on 18 October for Qlosi, which like the AbbVie product is a low-dose formulation of the ophthalmic drug pilocarpine. The Florida company said it will launch Qlosi and disclose the product’s pricing in early 2024, but indicated that it would price its product in the same range as Vuity.
Key Takeaways
-
Orasis obtained US FDA approval of Qlosi, a low-dose pilocarpine eyedrop to treat presbyopia, age-related loss of near vision.
Both products will compete primarily with reading glasses and Orasis president Paul Smith told Scrip that his company sees presbyopia...
